|Chemical and physical data|
|Molar mass||401.43 g·mol−1|
|3D model (JSmol)|
Evogliptin (INN; trade name Suganon) is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs. It was developed by the South Korean pharmaceutical company Dong-A ST and is approved for use in South Korea.
- McCormack PL. (2015). "Evogliptin: First Global Approval". Drugs. 75 (17): 2045–2049. doi:10.1007/s40265-015-0496-5. PMID 26541763.
- "Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea". pipelinereview.com. October 2, 2015.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|